عضویت در سایت

DYSLIPIDEMIA IN DIABETES

DYSLIPIDEMIA IN DIABETES

MAHTAB  NIROOMAND M.D.

Assistant professor of Endocrinology

SBUMS

Tehran 1391/11/19

 

Out-line

  • Pathophysiology and types of dyslipidemia in diabetic patients
  • Benefits of lipid- lowering therapy
  • Target lipid levels in diabetic patients
  • Combination therapy
  • Treatment of other lipoprotein fractions or targets
  • Statins and DM
  • ADA-2013 recommendation in lipid management in diabetic patients

Pathophysiology and types of dyslipidemia in DM

  • TG:
    • Key feature of diabetic dyslipidemia : increased production of VLDL by the liver in response to elevations in FFAs.
    • Insulin mediates the uptake of FFAs by striated muscle, reducing the levels presented to the liver,
    •  Insulin resistance results in the opposite effect, increasing the levels of FFAs available to the liver.
    • in T2DM : Reduced lipoprotein lipase activity leads to an accumulation of triglyceride-rich lipoproteins in the plasma.
    • TG-rich lipoproteins also reduced levels of HDL-C by increasing the transfer of cholesterol from these particles.
  • HDL-C:
    • levels of HDL-c (cardioprotective lipid fraction), are decreased.
    • The HDL-C  may also be less effective at protecting LDL-C  from oxidative stress
  • LDL-C:
    • LDL-C particles are generally smaller and more dense than typical LDL-C particles.
    • Small, dense LDL-C particles are more susceptible to oxidation, particularly in the setting of poor glucose control.
    • Glycation of LDL in diabetes, impairing recognition of the lipoprotein by its hepatoreceptor and extending its half-life.